{"id":"https://openalex.org/W2950182298","doi":"https://doi.org/10.1097/01.hs9.0000563964.92802.c3","title":"PS1422 VENETOCLAX FOR THE TREATMENT OF MULTIPLE MYELOMA: OUTCOMES OUTSIDE OF CLINICAL TRIALS","display_name":"PS1422 VENETOCLAX FOR THE TREATMENT OF MULTIPLE MYELOMA: OUTCOMES OUTSIDE OF CLINICAL TRIALS","publication_year":2019,"publication_date":"2019-06-01","ids":{"openalex":"https://openalex.org/W2950182298","doi":"https://doi.org/10.1097/01.hs9.0000563964.92802.c3","mag":"2950182298"},"language":"en","primary_location":{"id":"doi:10.1097/01.hs9.0000563964.92802.c3","doi":"https://doi.org/10.1097/01.hs9.0000563964.92802.c3","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000563964.92802.c3","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1097/01.hs9.0000563964.92802.c3","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004761196","display_name":"M Hasib Sidiqi","orcid":"https://orcid.org/0000-0003-1089-3853","observed_orcids":["https://orcid.org/0000-0003-1089-3853","https://orcid.org/0009-0006-9595-9258"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M.H. Sidiqi","raw_affiliation_strings":["Department of Hematology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001276883","display_name":"Abdullah S. Al Saleh","orcid":"https://orcid.org/0000-0003-1111-556X","observed_orcids":["https://orcid.org/0000-0003-1111-556X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A.S. Al Saleh","raw_affiliation_strings":["Department of Hematology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110128306","display_name":"Sudheer Kumar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118116","display_name":"Janssen (United Kingdom)","ror":"https://ror.org/02nw6hx08","country_code":"GB","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210118116"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Kumar","raw_affiliation_strings":["Department of Hematology","HEMAR, Janssen Ltd, High Wycombe, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"HEMAR, Janssen Ltd, High Wycombe, United Kingdom","institution_ids":["https://openalex.org/I4210118116"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012884078","display_name":"Morie Abraham Gertz","orcid":"https://orcid.org/0000-0002-3853-5196","observed_orcids":["https://orcid.org/0000-0002-3853-5196"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Morie","raw_affiliation_strings":["Department of Hematology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000308170","display_name":"Angela A. Dispenzieri","orcid":"https://orcid.org/0000-0001-8780-9512","observed_orcids":["https://orcid.org/0000-0001-8780-9512"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Dispenzieri","raw_affiliation_strings":["Department of Hematology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012403700","display_name":"Francis K. Buadi","orcid":"https://orcid.org/0000-0003-3214-0203","observed_orcids":["https://orcid.org/0000-0003-3214-0203"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Buadi","raw_affiliation_strings":["Department of Hematology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076611748","display_name":"Martha Q. Lacy","orcid":"https://orcid.org/0000-0003-1193-1559","observed_orcids":["https://orcid.org/0000-0003-1193-1559"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"M. Lacy","raw_affiliation_strings":["Department of Hematology","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":null,"display_name":"N. Leung","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"N. Leung","raw_affiliation_strings":["Department of Hematology","Division of Nephrology Mayo Clinic Rochester Rochester United States","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Division of Nephrology Mayo Clinic Rochester Rochester United States","institution_ids":["https://openalex.org/I1330342723"]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077686486","display_name":"Eli Muchtar","orcid":"https://orcid.org/0000-0003-2210-2174","observed_orcids":["https://orcid.org/0000-0003-2210-2174"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"E. Muchtar","raw_affiliation_strings":["Department of Hematology","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023193953","display_name":"Robert A. Kyle","orcid":"https://orcid.org/0000-0003-4763-4580","observed_orcids":["https://orcid.org/0000-0003-4763-4580"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"R. Kyle","raw_affiliation_strings":["Department of Hematology","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029802364","display_name":"Ronald S. Go","orcid":"https://orcid.org/0000-0002-8284-3495","observed_orcids":["https://orcid.org/0000-0002-8284-3495"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"R. Go","raw_affiliation_strings":["Department of Hematology","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110719204","display_name":"Miriam Hobbs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"M. Hobbs","raw_affiliation_strings":["Department of Hematology","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068637846","display_name":"Wilson I. Gonsalves","orcid":"https://orcid.org/0000-0001-6890-969X","observed_orcids":["https://orcid.org/0000-0001-6890-969X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Gonsalves","raw_affiliation_strings":["Department of Hematology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048259494","display_name":"Theodoros Kourelis","orcid":"https://orcid.org/0000-0002-2984-7120","observed_orcids":["https://orcid.org/0000-0002-2984-7120"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Kourelis","raw_affiliation_strings":["Department of Hematology","Open Analytics N.V., Antwerp"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Open Analytics N.V., Antwerp","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056260546","display_name":"Rahma M. Warsame","orcid":"https://orcid.org/0000-0003-0240-0326","observed_orcids":["https://orcid.org/0000-0003-0240-0326"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"R. Warsame","raw_affiliation_strings":["Department of Hematology","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007747233","display_name":"David Dingli","orcid":"https://orcid.org/0000-0001-7477-3004","observed_orcids":["https://orcid.org/0000-0001-7477-3004"]},"institutions":[{"id":"https://openalex.org/I4210128934","display_name":"Janssen (Germany)","ror":"https://ror.org/038rd9v60","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210128934"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"D. Dingli","raw_affiliation_strings":["Department of Hematology","HEMAR, Janssen Cilag GmbH, Neuss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"HEMAR, Janssen Cilag GmbH, Neuss, Germany","institution_ids":["https://openalex.org/I4210128934"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012411681","display_name":"JA Lust","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"J. Lust","raw_affiliation_strings":["Department of Hematology","HEMAR, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"HEMAR, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112254232","display_name":"Susan R. Hayman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"S. Hayman","raw_affiliation_strings":["Department of Hematology","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066940168","display_name":"S. Vincent Rajkumar","orcid":"https://orcid.org/0000-0002-5862-1833","observed_orcids":["https://orcid.org/0000-0002-5862-1833"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"V. Rajkumar","raw_affiliation_strings":["Department of Hematology","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033220547","display_name":"Prashant Kapoor","orcid":"https://orcid.org/0000-0002-4342-364X","observed_orcids":["https://orcid.org/0000-0002-4342-364X"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"P. Kapoor","raw_affiliation_strings":["Department of Hematology","Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology","institution_ids":[]},{"raw_affiliation_string":"Data Sciences, Janssen Pharmaceutica N.V., Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2480,"currency":"USD","value_usd":2480},"apc_paid":{"value":2480,"currency":"USD","value_usd":2480},"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"3","issue":"S1","first_page":"654","last_page":"655"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.996999979019165},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9639999866485596},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.8939999938011169},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.8309999704360962},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.6930000185966492},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.3499999940395355},{"id":"https://openalex.org/keywords/high-risk-cytogenetics","display_name":"high-risk cytogenetics","score":0.5559999942779541},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.6549999713897705},{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.9350000023841858},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.6620000004768372}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.9772969484329224},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7399129271507263},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7372210025787354},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5978496074676514},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5798028707504272},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5759069323539734},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.5612871646881104},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.5321221947669983},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5156630277633667},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4131730794906616},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2617923617362976},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.17036586999893188}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1097/01.hs9.0000563964.92802.c3","doi":"https://doi.org/10.1097/01.hs9.0000563964.92802.c3","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000563964.92802.c3","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1097/01.hs9.0000563964.92802.c3","doi":"https://doi.org/10.1097/01.hs9.0000563964.92802.c3","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000563964.92802.c3","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9907000064849854}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2980944890","https://openalex.org/W4405039128","https://openalex.org/W4405054914","https://openalex.org/W4405051467","https://openalex.org/W4409151123","https://openalex.org/W2979520565","https://openalex.org/W3096867320","https://openalex.org/W3114816661","https://openalex.org/W2890956331","https://openalex.org/W3107777078"],"abstract_inverted_index":{"Background:":[0],"Venetoclax":[1,244,499],"is":[2,43,500],"a":[3,15,55,102,127,249,263,289,299,379,438,468],"B":[4],"cell":[5],"lymphoma":[6],"2":[7],"(BCL\u20102)":[8],"inhibitor":[9,319],"that":[10,137],"has":[11],"shown":[12],"activity":[13],"as":[14,246],"single":[16],"agent":[17,504],"and":[18,50,54,66,117,170,190,217,262,283,305,320,325,451,455,489,510,514,533],"in":[19,24,62,71,90,156,251,255,267,329,360,495,505,517,530,536],"combination":[20,63,252,490,537],"with":[21,26,34,64,92,108,112,140,253,288,376,394,467,486,538],"other":[22,539],"therapies":[23,185,491],"patients":[25,72,91,107,136,196,211,261,311,339,352,363],"multiple":[27,93,109,146],"myeloma,":[28],"particularly":[29],"those":[30,385],"harboring":[31],"t(11;14)":[32,53,165,377],"associated":[33,466],"high":[35,178,395,412],"BCL\u20102":[36],"expression.":[37],"Although":[38],"early":[39],"clinical":[40,76,97,128],"trial":[41,77,129],"data":[42,68],"encouraging":[44],"(monotherapy":[45],"response":[46,56,358,366,382,420,430],"rate":[47,57,359,383],"of":[48,58,75,88,105,119,126,134,151,161,177,183,195,202,210,231,235,260,291,301,334,337,351,429,442],"21%":[49,191],"40%":[51],"amongst":[52],"97%":[59],"when":[60],"used":[61,245,328],"bortezomib":[65],"dexamethasone),":[67],"on":[69,167,317,354],"outcomes":[70,485],"treated":[73,95,111,139],"outside":[74,96,125],"setting":[78],"are":[79,154,453,492,523],"sparse.":[80],"Aims:":[81],"We":[82,100],"aimed":[83],"to":[84,233,314,402,419,525],"identify":[85],"the":[86,122,152,162,338,361,446,448,496,531],"efficacy":[87],"venetoclax":[89,113,141,236,287,355,487],"myeloma":[94,110,147,232,509],"trial.":[98],"Methods:":[99],"conducted":[101],"retrospective":[103],"review":[104],"all":[106],"between":[114],"December":[115],"2016":[116],"February":[118],"2019":[120],"at":[121,273,315],"Mayo":[123],"Clinic":[124],"setting.":[130],"Results:":[131],"A":[132],"total":[133],"29":[135],"were":[138,148,222,312,399,465],"for":[142,365,406,411,445,478],"relapsed":[143,506],"or":[144,225,248,265,277,294],"refractory":[145,224,313,508],"identified.":[149],"Characteristics":[150],"cohort":[153,163],"reported":[155,493],"Table":[157],"1.":[158],"Two":[159],"thirds":[160],"had":[164,175,197,212,298,378],"detected":[166],"cytogenetic":[168,397,463],"studies":[169,522],"48%":[171],"(n":[172,192,207,219,257,269,308,331,348],"=":[173,193,208,220,258,270,309,332,349,391,415,482],"14)":[174],"presence":[176],"risk":[179,396,408,462],"abnormalities.":[180],"Median":[181,227,417,427],"number":[182],"prior":[184,200,214],"was":[186,238,327,367,421,431],"6":[187],"(range":[188,241,424,434],"1\u201315)":[189],"6)":[194],"received":[198,213],"\u226510":[199],"lines":[201],"therapy.":[203,356],"Eighty":[204],"three":[205],"percent":[206],"24)":[209],"autologous":[215],"transplant":[216],"76%":[218],"22)":[221],"penta":[223],"exposed.":[226],"time":[228,418,441],"from":[229],"diagnosis":[230],"initiation":[234],"therapy":[237],"5.3":[239],"years":[240],"0.8\u201323.6":[242],"years).":[243],"monotherapy":[247,488],"doublet":[250],"dexamethasone":[254],"59%":[256],"17)":[259],"triplet":[264],"quadruplet":[266,284,300],"41%":[268],"12)":[271],"given":[272],"800":[274],"mg":[275,279],"(55%)":[276],"400":[278],"(35%)":[280],"daily.":[281],"Triplet":[282],"regimens":[285],"combined":[286],"variety":[290],"proteasome":[292,318],"inhibitors":[293],"daratumumab.":[295],"One":[296],"patient":[297],"venetoclax,":[302],"carfilzomib,":[303],"pomalidomide":[304],"dexamethasone.":[306],"93%":[307],"27)":[310],"least":[316],"immunomodulatory":[321],"drug.":[322],"Dose":[323],"titration":[324],"escalation":[326],"31%":[330],"9)":[333],"patients.":[335,520],"None":[336],"experienced":[340],"tumor":[341],"lysis":[342],"syndrome.":[343],"At":[344],"last":[345],"follow\u2010up":[346,440],"55%":[347],"16)":[350],"remain":[353],"Overall":[357],"24":[362],"evaluable":[364],"46%":[368],"(21%":[369],"CR,":[370],"8%":[371],"VGPR,":[372],"17%":[373],"PR).":[374],"Patients":[375,393],"numerically":[380],"higher":[381],"than":[384],"without":[386],"(50%":[387],"vs":[388,409,475],"33%,":[389],"p":[390,414,481],"0.64).":[392],"abnormalities":[398,464],"less":[400],"likely":[401],"respond":[403],"(ORR":[404],"69%":[405],"standard":[407,479],"18%":[410],"risk,":[413,480],"0.019).":[416],"2.6":[422],"months":[423,433,444,474,477],"1.1\u20136.9":[425],"months).":[426,436],"duration":[428],"5.2":[432],"2.2\u201312.9":[435],"After":[437],"median":[439,449],"7.2":[443],"cohort,":[447],"PFS":[450,470,472],"OS":[452],"5.8":[454],"14.6":[456],"months,":[457],"respectively,":[458],"Figure":[459],"1A/B.":[460],"High":[461],"shorter":[469],"(median":[471],"3":[473],"14":[476],"0.002).":[483],"The":[484],"separately":[494],"Table.":[497],"Summary/Conclusion:":[498],"an":[501],"effective":[502],"oral":[503],"and/or":[507],"can":[511],"produce":[512],"deep":[513],"durable":[515],"responses":[516],"heavily":[518],"pretreated":[519],"Further":[521],"needed":[524],"elucidate":[526],"its":[527,534],"role":[528],"earlier":[529],"disease":[532],"effectiveness":[535],"anti\u2010myeloma":[540],"therapies.":[541],"image":[542]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2019-06-27T00:00:00"}